Clinical Trial Update: Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of tislelizumab in locally advanced or metastatic urothelial bladder cancer has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Locally Advanced or Metastatic Urothelial Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-03-16